Therapy Areas: Oncology
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
3 November 2026 - Swedish oncology-focused development company Vivesto AB (STO:VIVE) said on Tuesday that it has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) f...
Lytix Biopharma's ruxotemitide combination meets primary endpoint in Phase II melanoma trial
3 November 2026 - Clinical-stage biotech company Lytix Biopharma ASA (Euronext Growth Oslo:LYTIX) announced on Tuesday that its Phase II NeoLIPA study evaluating ruxotemitide in combination with pembr...
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
2 November 2026 - INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercialising DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectiou...
Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101
30 October 2026 - Phrontline Biopharma, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), on Thursday reported encouraging preliminary clinical results...
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights
29 October 2026 - Biotechnology company TME Pharma N.V. (Euronext Growth Paris:ALTME) said on Thursday that it has signed a binding exclusive negotiation agreement with Japanese clinical-stage biotech...
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
28 October 2026 - Computational chemistry company Evogene Ltd (NASDAQ: EVGN) (TASE: EVGN) announced on Wednesday that it has selected acute graft-versus-host disease (aGVHD) as the target indication f...